000			02172 a2200637 4500
005			20250517092725.0
264		0	_c20170731
008			201707s 0 0 eng d
022			_a1590-3729
024	7		_a10.1016/j.numecd.2016.03.012 _2doi
040			_aNLM _beng _cNLM
100	1		_aWolf, P
245	0	0	_aSuppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. _h[electronic resource]
260			_bNutrition, metabolism, and cardiovascular diseases : NMCD _c05 2016
300			_a387-92 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdipose Tissue _xdrug effects
650	0	4	_aAged
650	0	4	_aAustria
650	0	4	_aBiomarkers _xblood
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDiabetic Cardiomyopathies _xblood
650	0	4	_aDown-Regulation
650	0	4	_aEnergy Metabolism _xdrug effects
650	0	4	_aFatty Acids, Nonesterified _xblood
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aHypolipidemic Agents _xadverse effects
650	0	4	_aLipolysis _xdrug effects
650	0	4	_aMagnetic Resonance Imaging
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyocardium _xmetabolism
650	0	4	_aProton Magnetic Resonance Spectroscopy
650	0	4	_aPyrazines _xadverse effects
650	0	4	_aRisk Factors
650	0	4	_aSingle-Blind Method
650	0	4	_aStroke Volume _xdrug effects
650	0	4	_aSystole
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aVentricular Function, Left _xdrug effects
700	1		_aWinhofer, Y
700	1		_aKrssak, M
700	1		_aSmajis, S
700	1		_aHarreiter, J
700	1		_aKosi-Trebotic, L
700	1		_aFürnsinn, C
700	1		_aAnderwald, C-H
700	1		_aBaumgartner-Parzer, S
700	1		_aTrattnig, S
700	1		_aLuger, A
700	1		_aKrebs, M
773	0		_tNutrition, metabolism, and cardiovascular diseases : NMCD _gvol. 26 _gno. 5 _gp. 387-92
856	4	0	_uhttps://doi.org/10.1016/j.numecd.2016.03.012 _zAvailable from publisher's website
999			_c25962361 _d25962361